Prolonged survival after intraperitoneal interleukin-2 immunotherapy for recurrent ovarian cancer

• A case report of a 14 year remission of recurrent ovarian cancer with intraperitoneal aldesleukin (IL-2) is presented. • Intraperitoneal IL-2 was given with little toxicity. • Immunotherapy may have the potential for durable remissions in ovarian cancer.

Detalles Bibliográficos
Autores principales: Minor, David R., Moores, Samantha P., Chan, John K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633818/
https://www.ncbi.nlm.nih.gov/pubmed/29034306
http://dx.doi.org/10.1016/j.gore.2017.09.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633818/
https://www.ncbi.nlm.nih.gov/pubmed/29034306
http://dx.doi.org/10.1016/j.gore.2017.09.009

Ejemplares similares